Mereo BioPharma Group PLC (LON:MPH) insider Denise Scots-Knight purchased 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was bought at an average price of GBX 54 ($0.71) per share, for a total transaction of £3,240 ($4,233.63).
Denise Scots-Knight also recently made the following trade(s):
- On Thursday, July 18th, Denise Scots-Knight purchased 10,000 shares of Mereo BioPharma Group stock. The stock was bought at an average price of GBX 51 ($0.67) per share, for a total transaction of £5,100 ($6,664.05).
Shares of LON MPH opened at GBX 54 ($0.71) on Monday. The company has a debt-to-equity ratio of 65.56, a quick ratio of 2.05 and a current ratio of 2.13. Mereo BioPharma Group PLC has a 52 week low of GBX 40 ($0.52) and a 52 week high of GBX 298 ($3.89). The stock has a market capitalization of $52.90 million and a P/E ratio of -1.20. The stock’s fifty day moving average is GBX 44.59 and its 200 day moving average is GBX 107.58.
Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.
Recommended Story: How interest rates affect municipal bond prices
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.